The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction-Reference-Cited by-同舟云学术

The Foundation for the National Institutes of Health Biomarkers Consortium: Past Accomplishments and New Strategic Direction

Published:2019-03-18 Issue:4 Volume:105 Page:829-843
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Menetski Joseph P.¹,Hoffmann Steven C.¹,Cush Stephanie S.¹,Kamphaus Tania Nayak¹,Austin Christopher P.²,Herrling Paul L.³,Wagner John A.⁴

Affiliation:

1. Foundation for the National Institutes of Health North Bethesda Maryland USA

2. National Center for Advancing Translational SciencesNational Institutes of Health Bethesda Maryland USA

3. Foundation for the National Institutes of Health Bethesda Maryland USA

4. Takeda Pharmaceuticals International Co. Cambridge Massachusetts USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.1362

Reference42 articles.

1. Biomarkers and Surrogate Endpoints: Clinical Research and Applications 2000 Elsevier Amsterdam UK G.L. Downing NIH Definitions Working Group Biomarkers and surrogate endpoints in clinical research: definitions and conceptual model 1 9

2. Biomarkers EndpointS and other Tools (BEST). .

3. Industry perspectives on biomarker qualification;Lavezzari G.;Clin. Pharmacol. Ther.,2016

4. The biomarkers consortium;Wholley D.;Nat. Rev. Drug Discov.,2014

5. The biomarkers consortium: practice and pitfalls of open‐source precompetitive collaboration;Wagner J.A.;Clin. Pharmacol. Ther.,2010

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Next-Generation Molecular Residual Disease Assays: Do We Have the Tools to Evaluate Them Properly?;Journal of Clinical Oncology;2024-08-10

2. Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry;Biomarkers;2024-04-29

3. Evaluation of biological markers for the risk assessment of carbon black in epidemiological studies;Frontiers in Public Health;2024-04-16

4. Current Trends in the Biomarker'sDiscovery for the Treatment and Management of Colorectal Cancer: A ComprehensiveReview;Current Medicinal Chemistry;2024-01-31

5. Neurobiosensors: novel approaches towards early diagnostics of neurodegenerative disorders;Smart Diagnostics for Neurodegenerative Disorders;2024